Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition. (2019)

Peer-Reviewed Study · Kristin Blom; Jenny Rubin; Malin Berglund et al. · April 22, 2019

Kristin Blom et al., 2019-04-22: Mechanistic follow-up proposing DYRK1B inhibition as part of the route by which mebendazole switches macrophages from M2 to M1.

MBZ potently binds and inhibits Dual specificity tyrosine-phosphorylation-regulated kinase 1B (DYRK1B) with a Kd and an IC50 of 7 and 360 nM, respectively.

Kristin Blom et al., 2019-04-22: Mechanistic follow-up proposing DYRK1B inhibition as part of the route by which mebendazole switches macrophages from M2 to M1. Study type: THP-1 monocyte/macrophage cell work with kinase binding assays. N: not applicable. Country: Sweden (Uppsala University). Dose: Kd 7 nM, IC50 360 nM for DYRK1B. Funder: Cancerfonden grant 'Can 2016/335'. Declared conflicts: Repos Pharma AB shareholdings (RL, PN, MF); AL chairman of the board. PARTLY because the authors report that the specific DYRK1B inhibitor AZ191 did not reproduce mebendazole's cytokine profile in untreated monocytes, so the mechanism is offered as partial.